Results 11 to 20 of about 29,991,050 (179)

Evaluation of the value of preoperative CYFRA21-1 in the diagnosis and prognosis of epithelial ovarian cancer in conjunction with CA125 [PDF]

Journal of Ovarian Research, 2019
Growing evidence indicates that the tumor biomarker cytokeratin 19 fragment (CYFRA21-1) is significant for a variety of cancers. However, its role in epithelial ovarian cancer (EOC) has rarely been reported.
Chunjing Jin, Minfeng Yang, Xueqiao Han, Haidan Chu, Yan Zhang, Meihong Lu, Zhonghui Wang, Xinxin Xu, Wenwen Liu, Feng Wang, Shaoqing Ju   +10 more
doaj   +3 more sources

Serum keratin 19 (CYFRA21-1) links ductular reaction with portal hypertension and outcome of various advanced liver diseases [PDF]

BMC Medicine, 2020
Background Keratins (Ks) represent tissue-specific proteins. K18 is produced in hepatocytes while K19, the most widely used ductular reaction (DR) marker, is found in cholangiocytes and hepatic progenitor cells.
Karim Hamesch, Nurdan Guldiken, Mahmoud Aly, Norbert Hüser, Daniel Hartmann, Pierre Rufat, Marianne Ziol, Katharina Remih, Georg Lurje, Bernhard Scheiner, Christian Trautwein, Mattias Mandorfer, Thomas Reiberger, Sebastian Mueller, Tony Bruns, Pierre Nahon, Pavel Strnad   +16 more
doaj   +4 more sources

Clinical Value of Pleural Effusion and Serum MMP-3 and CYFRA21-1 Combined with ADA in Differential Diagnosis of Pleural Exudative Effusion

Emergency Medicine International, 2022
Objective. The aim of the study is to investigate the clinical value of matrix metalloproteinases-3 (MMP-3) and cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) combined with adenosine deaminase (ADA) in pleural effusion and serum in benign and malignant
Zhiyang Xu, Jun Guan, Jianxin Xu, Jiahua Tu, Jiangdong Cheng   +4 more
doaj   +3 more sources

Analysis of variation of serum CEA, SCC, CYFRA21-1 in patients with lung cancer and their diagnostic value with EBUS-TBNA [PDF]

Journal of Medical Biochemistry
Background: To explore the variation of serum carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), and squamous cell carcinoma (SCC) antigen in patients with lung cancer (LC) and their diagnostic value with endobronchial ultrasound-guided
Du Yanjia, Wen Ya, Huang Jieyu
doaj   +4 more sources

Diagnosis Value of the Detection of CYFRA21-1 in Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2010
Background and objective Cytokeratin-19 fragment (CYFRA21-1) is a soluble protein in serum, and may be a useful circulating tumor marker. The aim of this study is to investigate the diagnostic value of the peripheral blood CYFRA21-1 in non-small cell ...
Jundong GU, Xinzhuo WANG, Hui ZHAO, Siwei ZHU, Yanjun WEN, Hongrui XU, Li LI, Jun CHEN, Qinghua ZHOU   +8 more
doaj   +3 more sources

Usefulness of Circulating CYFRA21-1 in Patients as a Biomarker in Patients Taking Sorafenib or Lenvatinib for Unresectable Hepatocellular Carcinoma

Reports, 2021
Background: This study investigated the impact of serum cytokeratin 19 fragment (CYFRA21-1) level on the clinical outcomes of patients with unresectable hepatocellular carcinoma (HCC) treated with sorafenib (SOR) or lenvatinib (LEN).
Hitomi Takada, Leona Osawa, Yasuyuki Komiyama, Ryoh Kato, Natsuko Nakakuki, Masaru Muraoka, Yuichiro Suzuki, Akihisa Tatsumi, Mitsuaki Sato, Ei Takahashi, Shinichi Takano, Mitsuharu Fukasawa, Tatsuya Yamaguchi, Taisuke Inoue, Shinya Maekawa, Nobuyuki Enomoto   +15 more
doaj   +2 more sources

Variations in Serum CEA and CYFRA21-1 Levels Before and After Surgery Facilitate Prognosis of Non-small Cell Lung Cancer Patients

Chinese Journal of Lung Cancer, 2015
Background and objective Serum carcinoembryonic antigen (CEA) and the soluble fragment of cytokeratin 19 (CYFRA21-1) are important tumor markers (TMs) in the preoperative examination of patients with non-small cell lung cancer (NSCLC).
Xinchun DUAN, Yong CUI, Min GONG, Feng TIAN, Guan SHI, Bingqun WU, Mingliang LIU, Jiayun GUO, Yuanyuan KONG   +8 more
doaj   +2 more sources

Serum CYFRA21-1 is Correlated with the Efficacy of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients Harboring EGFR Mutations

Chinese Journal of Lung Cancer, 2016
Background and objective Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the standard first-line treatment regimen for EGFR mutated non-small cell lung cancer (NSCLC) patients. However, the efficacy of EGFR-TKIs widely varies.
Qunhui WANG, Hua ZHENG, Fanbin HU, Hongmei ZHANG, Ying HU, Jie LI, Tongmei ZHANG, Zan LIU, Baohua LU, Aimin HU, Baolan LI   +10 more
doaj   +2 more sources

Preoperative Cyfra21-1 and SCC-Ag serum titers predict survival in patients with stage II esophageal squamous cell carcinoma

Journal of Translational Medicine, 2012
Background The purpose of this study is to evaluate the predictive significance of preoperative serum level of cytokeratin 19 fragments (Cyfra21-1) and squamous cell carcinoma antigen (SCC-Ag) after complete resection in patients with stage II esophageal
Cao Xun, Zhang Lin, Feng Gui-Rong, Yang Juan, Wang Ruo-Yan, Li Jun, Zheng Xiao-Min, Han Yu-Jing   +7 more
doaj   +2 more sources

The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients [PDF]

Journal of Translational Medicine, 2019
Background CEA, CYFRA21-1 and NSE are tumor markers used for monitoring the response to chemotherapy in advanced adenocarcinoma, squamous cell carcinoma and small-cell lung cancer, respectively.
M. G. Dal Bello, R. A. Filiberti, A. Alama, A. M. Orengo, M. Mussap, S. Coco, I. Vanni, S. Boccardo, E. Rijavec, C. Genova, F. Biello, G. Barletta, G. Rossi, M. Tagliamento, C. Maggioni, F. Grossi   +15 more
doaj   +2 more sources